News & Updates
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for treatment of neurodegenerative diseases, today announced that DNL151 has been selected to progress into late stage studies…
Read More
Excerpt from the Article: It was purely by chance that at the very moment Ala Stanford walked into a revival service at a Philly church last summer, a man fainted and was suddenly unable to move or speak. Frantic and afraid, the man’s wife, a friend of Stanford’s, asked the board-certified surgeon to ride in…
Read More
Excerpt from the Article: BC Children’s Hospital is pleased to congratulate the recipients of the 2020 BCCHR Studentships and Fellowships. These awards give exceptional trainees the opportunity to pursue leading-edge child health research projects under the supervision of BC Children’s Hospital Investigators. BCCHR Studentships and Fellowships are made possible through the support of BC Children’s…
Read More
Excerpt from the Press Release: Burlingame, CA, August 10, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase…
Read More
Excerpt from the article: Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences…
Read More
Excerpt from the Article: “In April, San Diego’s Dexcom saw a slowdown in patients signing up for its continuous glucose monitors as consumers hunkered down and doctors transitioned to tele-medicine because of the COVID-19 pandemic. The question was how long would the dip last? As it turned out, not very long. As physicians and patients…
Read More
Excerpt from the Press Release: BOSTON, July 29, 2020 /PRNewswire/ — Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference (AAIC 2020). PU-AD is Samus’…
Read More
Excerpt from the article: “In late January, when hospitals in the United States confirmed the presence of the novel coronavirus, health workers knew to watch for precisely three symptoms: fever, cough, and shortness of breath. But as the number of infections climbed, the symptom list began to grow. Some patients lost their sense of smell…
Read More
Excerpt from the Article: “San Diego start-up Truvian Sciences has received federal emergency approval for a blood test that detects COVID-19 antibodies in as little as 10 minutes. Called Easy Check, the portable test will be sold by Truvian to health professionals for about $15 and has an accuracy rate in excess of 98 percent,…
Read More
Excerpt from the Press Release: “FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced positive results from its completed Phase 1 single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor,…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?